Philippe Aftimos, MD · @aftimosp · X·· 14 小时前评分70
正文 · 原文
I very much enjoyed the discussion by @StephenVLiu of DeLLphi-305 (tarlatamab + durvalumab as maintenance therapy in ES-SCLC at #ESMO26
👏👏👏
#ESMOAmbassadors
25 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Philippe Aftimos, MD · x.com